
Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries

Knight GM, Griffiths UK, Sumner T, Laurence YV, Gheorghe A, Vassall A, Glaziou P, White RG

Record Status

This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Knight GM, Griffiths UK, Sumner T, Laurence YV, Gheorghe A, Vassall A, Glaziou P, White RG. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. *Proceedings of the National Academy of Sciences of the United States of America* 2014; 111(43): 15520-15525

PubMedID

[25288770](#)

DOI

10.1073/pnas.1404386111

Indexing Status

Subject indexing assigned by NLM

MeSH

Adolescent; Adult; Calibration; Cost-Benefit Analysis; Developing Countries /economics; Humans; Income; Infant; Models, Economic; Tuberculosis /economics /immunology /mortality /prevention & control; Tuberculosis Vaccines /economics; Uncertainty

AccessionNumber

22014038573

Date bibliographic record published

11/12/2014